S. R. Rangus
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
S. R. Rangus has a total of 18 co-authors. Here are the top co-authors by number of shared publications:
- A. O. Prosvetov
Evdokimov Moscow State Medical and Dental University, Russian Ministry of Health, Moscow, Russia
4 shared publications - Boris Dmitrievich Tsygankov
FSBEI HE Russian University of Medicine of the Ministry of Health of the Russian Federation
4 shared publications - E. V. Kuznetsov
Evdokimov Moscow State University of Medicine and Dentistry, Moscow, Russia
2 shared publications Federal State Budgetary Educational Institution of Higher Education «A. I. Yevdokimov Moscow State University of Medicine and Dentistry» of the Ministry of Health of the Russian Federation
2 shared publicationsA.I. Yevdokimov Moscow State University of Medicine and Dentistry"
1 shared publication- Alla B. Guekht
Moscow Research and Clinical Center for Neuropsychiatry
1 shared publication
Latest Publications
- 25 May 2023
- Published by PANORAMA Publishing House in Vestnik Nevrologii, Psihiatrii i Nejrohirurgii (Bulletin of Neurology, Psychiatry and Neurosurgery)
- No. 6,p. 467-475
Transcranial magnetic stimulation in the complex therapy of treatment-resistant depressions complicated by residual organic insufficiency of the central nervous system
- 25 May 2023
- Published by PANORAMA Publishing House in Vestnik Nevrologii, Psihiatrii i Nejrohirurgii (Bulletin of Neurology, Psychiatry and Neurosurgery)
- No. 6,p. 467-475
Transcranial magnetic stimulation in the complex therapy of treatment-resistant depressions complicated by residual organic insufficiency of the central nervous system
- 25 March 2023
- Published by PANORAMA Publishing House in Vestnik Nevrologii, Psihiatrii i Nejrohirurgii (Bulletin of Neurology, Psychiatry and Neurosurgery)
- No. 4,p. 241-255
Transcranial magnetic stimulation for treatment-resistant depression in patients with residual-organic insufficiency of the central nervous system
This article discusses the relationship of three global topics, each of which is of particular interest in the scientific community: transcranial magnetic stimulation as a treatment method, treatment-resistant depression, and residual-organic insufficiency of the central nervous system. Depression has become one of the most common diseases in the world, affecting more than 264 million people. According to various clinical data, drug therapy is effective in about 70 % of cases. In the remaining 30 %, there is no efficiency, or it turns out to be incomplete. These conditions can be comorbid with a variety of exogenous organic symptoms. Up to 30 % of patients seeking medical help in connection with neurotic disorders have signs of residual-organic insufficiency. The treatment of these conditions requires the search for methods to resolve them. One of these methods is transcranial magnetic stimulation. It is a non-invasive and well-tolerated treatment for depression, with proven clinical efficacy.
- 25 March 2023
- Published by PANORAMA Publishing House in Vestnik Nevrologii, Psihiatrii i Nejrohirurgii (Bulletin of Neurology, Psychiatry and Neurosurgery)
- No. 4,p. 241-255
Transcranial magnetic stimulation for treatment-resistant depression in patients with residual-organic insufficiency of the central nervous system
This article discusses the relationship of three global topics, each of which is of particular interest in the scientific community: transcranial magnetic stimulation as a treatment method, treatment-resistant depression, and residual-organic insufficiency of the central nervous system. Depression has become one of the most common diseases in the world, affecting more than 264 million people. According to various clinical data, drug therapy is effective in about 70 % of cases. In the remaining 30 %, there is no efficiency, or it turns out to be incomplete. These conditions can be comorbid with a variety of exogenous organic symptoms. Up to 30 % of patients seeking medical help in connection with neurotic disorders have signs of residual-organic insufficiency. The treatment of these conditions requires the search for methods to resolve them. One of these methods is transcranial magnetic stimulation. It is a non-invasive and well-tolerated treatment for depression, with proven clinical efficacy.
- 1 January 2023
- Published by PANORAMA Publishing House in Vestnik Nevrologii, Psihiatrii i Nejrohirurgii (Bulletin of Neurology, Psychiatry and Neurosurgery)
- No. 1,p. 8-19
Transcranial magnetic stimulation and SSRIs in the complex treatment of Parkinson’s disease patients with depressive disorders
Affective disorders in patients with Parkinson's disease (PD) are significantly more common than in the general population in people of the same age. It is known that the ef ficacy of antidepressants in PD patients is lower than in patients with a depressive disorder not associated with PD. Therefore, such patients may take high doses of antidepressants, which is accompanied by side effects manifestations and a decrease in quality of life. Transcranial magnetic stimulation (TMS) is a safe treatment for depressive disorder that has been successfully used in PD patients. The article presents a comparison of the effectiveness of complex therapy with TMS and SSRIs with SSRI monotherapy for the treatment of depressive disorder in PD patient.
- 1 January 2023
- Published by PANORAMA Publishing House in Vestnik Nevrologii, Psihiatrii i Nejrohirurgii (Bulletin of Neurology, Psychiatry and Neurosurgery)
- No. 1,p. 8-19
Transcranial magnetic stimulation and SSRIs in the complex treatment of Parkinson’s disease patients with depressive disorders
Affective disorders in patients with Parkinson's disease (PD) are significantly more common than in the general population in people of the same age. It is known that the ef ficacy of antidepressants in PD patients is lower than in patients with a depressive disorder not associated with PD. Therefore, such patients may take high doses of antidepressants, which is accompanied by side effects manifestations and a decrease in quality of life. Transcranial magnetic stimulation (TMS) is a safe treatment for depressive disorder that has been successfully used in PD patients. The article presents a comparison of the effectiveness of complex therapy with TMS and SSRIs with SSRI monotherapy for the treatment of depressive disorder in PD patient.
- 1 January 2022
- Published by Media Sphere Publishing Group in S.S. Korsakov Journal of Neurology and Psychiatry
- Vol. 122 (9) , 79-85
Transcranial magnetic stimulation in the treatment of depressive disorder in Parkinson’s disease
Распространенность аффективных нарушений у пациентов с болезнью Паркинсона (БП) значительно выше, чем в общей популяции у лиц того же возраста. Известно, что эффективность антидепрессантов при БП с депрессивным расстройством ниже, чем у пациентов с первичной депрессией. При депрессии, резистентной к стандартной фармакотерапии, доступны другие терапевтические стратегии. Транскраниальная магнитная стимуляция — это один из самых популярных и безопасных методов стимуляции мозга, который успешно применяется для лечения первичной депрессии. Накопление опыта использования транскраниальной магнитной стимуляции позволило расширить применение метода на другие нозологии, включая БП. В статье отражены данные литературы о применении разных протоколов транскраниальной магнитной стимуляции для лечения депрессивного расстройства у пациентов с БП.
- 1 January 2022
- Published by Media Sphere Publishing Group in S.S. Korsakov Journal of Neurology and Psychiatry
- Vol. 122 (9) , 79-85
Transcranial magnetic stimulation in the treatment of depressive disorder in Parkinson’s disease
Распространенность аффективных нарушений у пациентов с болезнью Паркинсона (БП) значительно выше, чем в общей популяции у лиц того же возраста. Известно, что эффективность антидепрессантов при БП с депрессивным расстройством ниже, чем у пациентов с первичной депрессией. При депрессии, резистентной к стандартной фармакотерапии, доступны другие терапевтические стратегии. Транскраниальная магнитная стимуляция — это один из самых популярных и безопасных методов стимуляции мозга, который успешно применяется для лечения первичной депрессии. Накопление опыта использования транскраниальной магнитной стимуляции позволило расширить применение метода на другие нозологии, включая БП. В статье отражены данные литературы о применении разных протоколов транскраниальной магнитной стимуляции для лечения депрессивного расстройства у пациентов с БП.